These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

403 related items for PubMed ID: 16984998

  • 1. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients.
    Jäger E, Karbach J, Gnjatic S, Neumann A, Bender A, Valmori D, Ayyoub M, Ritter E, Ritter G, Jäger D, Panicali D, Hoffman E, Pan L, Oettgen H, Old LJ, Knuth A.
    Proc Natl Acad Sci U S A; 2006 Sep 26; 103(39):14453-8. PubMed ID: 16984998
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing Tumors.
    Bioley G, Guillaume P, Luescher I, Bhardwaj N, Mears G, Old L, Valmori D, Ayyoub M.
    J Immunother; 2009 Sep 26; 32(2):161-8. PubMed ID: 19238015
    [Abstract] [Full Text] [Related]

  • 4. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF.
    Sharma P, Bajorin DF, Jungbluth AA, Herr H, Old LJ, Gnjatic S.
    J Immunother; 2008 Sep 26; 31(9):849-57. PubMed ID: 18833002
    [Abstract] [Full Text] [Related]

  • 5. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma.
    Nicholaou T, Ebert LM, Davis ID, McArthur GA, Jackson H, Dimopoulos N, Tan B, Maraskovsky E, Miloradovic L, Hopkins W, Pan L, Venhaus R, Hoffman EW, Chen W, Cebon J.
    Clin Cancer Res; 2009 Mar 15; 15(6):2166-73. PubMed ID: 19276262
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo.
    Garcia Casado J, Janda J, Wei J, Chapatte L, Colombetti S, Alves P, Ritter G, Ayyoub M, Valmori D, Chen W, Lévy F.
    Eur J Immunol; 2008 Jul 15; 38(7):1867-76. PubMed ID: 18546142
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.
    Zarour HM, Maillere B, Brusic V, Coval K, Williams E, Pouvelle-Moratille S, Castelli F, Land S, Bennouna J, Logan T, Kirkwood JM.
    Cancer Res; 2002 Jan 01; 62(1):213-8. PubMed ID: 11782380
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients.
    Shang XY, Chen HS, Zhang HG, Pang XW, Qiao H, Peng JR, Qin LL, Fei R, Mei MH, Leng XS, Gnjatic S, Ritter G, Simpson AJ, Old LJ, Chen WF.
    Clin Cancer Res; 2004 Oct 15; 10(20):6946-55. PubMed ID: 15501973
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad antibody responses in humans, a RAYS-based analysis.
    Mischo A, Bubel N, Cebon JS, Samaras P, Petrausch U, Stenner-Liewen F, Schaefer NG, Kubuschok B, Renner C, Wadle A.
    Int J Oncol; 2011 Jul 15; 39(1):287-94. PubMed ID: 21573493
    [Abstract] [Full Text] [Related]

  • 16. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51.
    Jäger E, Karbach J, Gnjatic S, Jäger D, Maeurer M, Atmaca A, Arand M, Skipper J, Stockert E, Chen YT, Old LJ, Knuth A.
    Cancer Immun; 2002 Sep 19; 2():12. PubMed ID: 12747757
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design.
    Ebert LM, Liu YC, Clements CS, Robson NC, Jackson HM, Markby JL, Dimopoulos N, Tan BS, Luescher IF, Davis ID, Rossjohn J, Cebon J, Purcell AW, Chen W.
    Cancer Res; 2009 Feb 01; 69(3):1046-54. PubMed ID: 19176376
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.